BBNX.NASDAQBeta Bionics, INC

SCHEDULE 13G: RTW Investments Discloses 7.6% Stake in Beta Bionics, Inc.

Sentiment:

Beneficial Ownership Report

📋All filings for Beta Bionics, INC
🔒Login to Follow

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a beneficial ownership of 7.6% in Beta Bionics, Inc., totaling 3,299,869 shares of common stock.

Summary

  • RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating beneficial ownership of Beta Bionics, Inc. common stock.
  • The Reporting Persons collectively beneficially own 3,299,869 shares of Beta Bionics, Inc. common stock.
  • This ownership represents 7.6% of the company's outstanding common stock, based on 43,348,840 shares outstanding as of March 1, 2025, as reported in the company's Annual Report on Form 10-K filed on March 28, 2025.
  • Both RTW Investments, LP and Roderick Wong, M.D. hold shared voting power and shared dispositive power over all 3,299,869 shares.
  • The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the disclosure of a significant institutional ownership stake can be perceived as a vote of confidence in the company, although the filing itself is purely factual and regulatory.

Positives

  • The disclosure of a significant stake (7.6%) by an institutional investment firm like RTW Investments, LP, and its Managing Partner, Roderick Wong, M.D., can be viewed as a vote of confidence in Beta Bionics, Inc.

Future Outlook

No specific forward-looking statements or guidance from Beta Bionics, Inc. are provided in this beneficial ownership filing, as it pertains solely to the disclosure of an ownership stake by an investment firm.

Industry Context

RTW Investments, LP is an investment adviser, and their significant stake in Beta Bionics, Inc. indicates institutional interest in the company, which operates in the 'Bionics' sector, likely related to medical devices or biotechnology.

Stakeholder Impact

  • Shareholders: The disclosure of a significant institutional investor holding a 7.6% stake provides transparency regarding the company's ownership structure and may influence investor perception.

Key Dates

DateDescription
March 1, 2025Date as of which 43,348,840 shares of Beta Bionics, Inc. common stock were reported outstanding in the company's Annual Report on Form 10-K.
March 28, 2025Date Beta Bionics, Inc. filed its Annual Report on Form 10-K with the SEC.
March 31, 2025Date of the event which required the filing of this Schedule 13G statement.
May 15, 2025Date the Schedule 13G statement was signed by RTW Investments, LP and Roderick Wong, M.D.

Keywords

Beta Bionics, RTW Investments, Roderick Wong, Schedule 13G, beneficial ownership, institutional investment, common stock, equity stake

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.